Zhang Yan, Zhong Qiang, Luo Xiaochun, Zhang Wei
Department of Gastroenterology, Xiamen Humanity Hospital, Fujian Medical University Xiamen, Fujian, China.
Department of Gastroenterology, Beijing Pinggu Hospital Beijing, China.
Am J Transl Res. 2022 Nov 15;14(11):7969-7976. eCollection 2022.
To explore the effects of Tegafur, Gimeracil and Oteracil Potassium Capsules (TGOPC) combined with Calf Spleen Extractive Injection (CSEI) on vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients with advanced gastric cancer.
A retrospective analysis was conducted on data of 118 patients with advanced gastric cancer treated in Anyang Tumor Hospital from January 2016 to September 2018. The patients were divided into two groups according to treatment modalities, with control group receiving Oxaliplatin and TGOPC and observation group receiving Oxaliplatin, TGOPC and CSEI. Clinical efficacy, changes of serum VEGF and MMP-9 before and after chemotherapy, survival rate and incidence of adverse reactions were compared between the two groups.
The number of responded patients was 36 (61.02%) in the observation group and was 18 (30.51%) in the control group (<0.05). The levels of serum VEGF and MMP-9, and incidence of nausea and vomiting in the observation group were lower than those in the control group (<0.05). The 1-year and 2-year survival rates in the observation group were higher than those in the control group (<0.05).
The use of CSEI on the basis of Oxaliplatin combined with TGOPC chemotherapy for the treatment of advanced gastric cancer could further improve the clinical efficacy and survival rate, and reduce the incidence of adverse reactions.
探讨替吉奥胶囊（TGOPC）联合小牛脾提取物注射液（CSEI）对晚期胃癌患者血管内皮生长因子（VEGF）和基质金属蛋白酶-9（MMP-9）的影响。
对2016年1月至2018年9月在安阳市肿瘤医院治疗的118例晚期胃癌患者的数据进行回顾性分析。根据治疗方式将患者分为两组，对照组接受奥沙利铂和替吉奥胶囊治疗，观察组接受奥沙利铂、替吉奥胶囊和小牛脾提取物注射液治疗。比较两组的临床疗效、化疗前后血清VEGF和MMP-9的变化、生存率及不良反应发生率。
观察组有效患者36例（61.02%），对照组18例（30.51%）（P<0.05）。观察组血清VEGF和MMP-9水平及恶心呕吐发生率低于对照组（P<0.05）。观察组1年和2年生存率高于对照组（P<0.05）。
在奥沙利铂联合替吉奥胶囊化疗基础上使用小牛脾提取物注射液治疗晚期胃癌，可进一步提高临床疗效和生存率，降低不良反应发生率。
